Arax Advisory Partners’s Haemonetics HAE Stock Holding History

Arax Advisory Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$879K	Buy	11,716 +11,583	+8,709%	+$744K	0.01%	1295
2026 Q1	$7.5K	Sell	133 -127	-49%	-$8.27K	﹤0.01%	2597
2025 Q4	$20.8K	Sell	260 -10,153	-98%	-$682K	﹤0.01%	2088
2025 Q3	$508K	Buy	10,413 +9,789	+1,569%	+$606K	0.01%	895
2025 Q2	$46.6K	Buy	624 +609	+4,060%	+$40.3K	﹤0.01%	1274
2025 Q1	$954	Buy	15 +6	+67%	+$408	﹤0.01%	2316
2024 Q4	$703	Sell	9 -30	-77%	-$2.41K	﹤0.01%	2248
2024 Q3	$3.13K	Hold	39	–	–	﹤0.01%	1905
2024 Q2	$3.23K	Buy	+39	New	+$3.43K	﹤0.01%	1793
2023 Q4	–	Sell	-7	Closed	-$628	–	1377
2023 Q3	$628	Sell	7 -13	-65%	-$1.16K	﹤0.01%	1214
2023 Q2	$1.7K	Sell	20 -18	-47%	-$1.52K	﹤0.01%	1028
2023 Q1	$3.15K	Buy	38 +25	+192%	+$2.02K	﹤0.01%	942
2022 Q4	$1.02K	Hold	13	–	–	﹤0.01%	1067
2022 Q3	$1K	Buy	+13	New	+$933	﹤0.01%	1081

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's HAE Position: Q2 2026 in Review

Arax Advisory Partners increased its Haemonetics (HAE) stake by 8,709% in Q2 2026, buying an estimated $744K and bringing the position to 11,716 shares worth $879K. The position accounts for 0.01% of the portfolio, ranked #1295.

Arax Advisory Partners first reported a position in HAE in Q3 2022 and has held it in 14 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Arax Advisory Partners held 11,716 shares of Haemonetics worth $879K as of Q2 2026.
Arax Advisory Partners bought 11,583 Haemonetics shares in Q2 2026, an estimated $744K.
Haemonetics made up 0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1295 holding.
Arax Advisory Partners first reported a position in Haemonetics in Q3 2022 and has held it in 14 quarters since.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.